<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - BOCEPREVIR</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>BOCEPREVIR</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic hepatitis C infection of genotype 1 in patients with compensated liver disease (in combination with ribavirin and peginterferon alfa)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                800 mg 3 times a day, for duration of treatment consult product literature.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Appendix 1 (boceprevir).</p> <p>Caution with concomitant use of other drugs known to prolong QT interval.</p>
            </section>
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Autoimmune hepatitis</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain (in combination with ribavirin and peginterferon alfa), agitation (in combination with ribavirin and peginterferon alfa), alopecia (in combination with ribavirin and peginterferon alfa), amnesia (in combination with ribavirin and peginterferon alfa), anaemia (in combination with ribavirin and peginterferon alfa), anxiety (in combination with ribavirin and peginterferon alfa), arthralgia (in combination with ribavirin and peginterferon alfa), asthenia (in combination with ribavirin and peginterferon alfa), blood pressure changes (in combination with ribavirin and peginterferon alfa), changes in libido (in combination with ribavirin and peginterferon alfa), constipation (in combination with ribavirin and peginterferon alfa), cough (in combination with ribavirin and peginterferon alfa), decreased appetite (in combination with ribavirin and peginterferon alfa), depression (in combination with ribavirin and peginterferon alfa), diarrhoea (in combination with ribavirin and peginterferon alfa), disturbances in smell (in combination with ribavirin and peginterferon alfa), disturbances in taste (in combination with ribavirin and peginterferon alfa), dizziness (in combination with ribavirin and peginterferon alfa), dry eyes (in combination with ribavirin and peginterferon alfa), dry mouth (in combination with ribavirin and peginterferon alfa), dyspnoea (in combination with ribavirin and peginterferon alfa), erectile dysfunction (in combination with ribavirin and peginterferon alfa), flatulence (in combination with ribavirin and peginterferon alfa), gastro-oesophageal reflux (in combination with ribavirin and peginterferon alfa), haemorrhoids (in combination with ribavirin and peginterferon alfa), headache (in combination with ribavirin and peginterferon alfa), hyperglycaemia (in combination with ribavirin and peginterferon alfa), hyperhidrosis (in combination with ribavirin and peginterferon alfa), hypertriglyceridaemia (in combination with ribavirin and peginterferon alfa), hyperuricaemia (in combination with ribavirin and peginterferon alfa), hypoaesthesia (in combination with ribavirin and peginterferon alfa), hypothyroidism (in combination with ribavirin and peginterferon alfa), influenza-like symptoms (in combination with ribavirin and peginterferon alfa), insomnia (in combination with ribavirin and peginterferon alfa), leucopenia (in combination with ribavirin and peginterferon alfa), mouth ulcers (in combination with ribavirin and peginterferon alfa), muscle spasms (in combination with ribavirin and peginterferon alfa), myalgia (in combination with ribavirin and peginterferon alfa), nausea (in combination with ribavirin and peginterferon alfa), palpitation (in combination with ribavirin and peginterferon alfa), pancytopenia (in combination with ribavirin and peginterferon alfa), paraesthesia (in combination with ribavirin and peginterferon alfa), peripheral oedema (in combination with ribavirin and peginterferon alfa), polyuria (in combination with ribavirin and peginterferon alfa), pruritus (in combination with ribavirin and peginterferon alfa), psoriasis (in combination with ribavirin and peginterferon alfa), rash (in combination with ribavirin and peginterferon alfa), stomatitis (in combination with ribavirin and peginterferon alfa), syncope (in combination with ribavirin and peginterferon alfa), thrombocytopenia (in combination with ribavirin and peginterferon alfa), tinnitus (in combination with ribavirin and peginterferon alfa), tooth disorder (in combination with ribavirin and peginterferon alfa), tremor (in combination with ribavirin and peginterferon alfa), visual disturbances (in combination with ribavirin and peginterferon alfa), vomiting (in combination with ribavirin and peginterferon alfa), weight loss (in combination with ribavirin and peginterferon alfa),
              </p>
              <p>
                <strong>uncommon:</strong> Amenorrhoea (in combination with ribavirin and peginterferon alfa), arrhythmias (in combination with ribavirin and peginterferon alfa), colitis (in combination with ribavirin and peginterferon alfa), conjunctival haemorrhage (in combination with ribavirin and peginterferon alfa), dysphagia (in combination with ribavirin and peginterferon alfa), dysphonia (in combination with ribavirin and peginterferon alfa), dysuria (in combination with ribavirin and peginterferon alfa), eye pain (in combination with ribavirin and peginterferon alfa), flushing (in combination with ribavirin and peginterferon alfa), gingivitis (in combination with ribavirin and peginterferon alfa), gout (in combination with ribavirin and peginterferon alfa), hearing impairment (in combination with ribavirin and peginterferon alfa), homicidal ideation (in combination with ribavirin and peginterferon alfa), hyperaesthesia (in combination with ribavirin and peginterferon alfa), hyperbilirubinaemia (in combination with ribavirin and peginterferon alfa), hypercalcaemia (in combination with ribavirin and peginterferon alfa), hypersalivation (in combination with ribavirin and peginterferon alfa), hyperthyroidism (in combination with ribavirin and peginterferon alfa), hypokalaemia (in combination with ribavirin and peginterferon alfa), increased lacrimation (in combination with ribavirin and peginterferon alfa), menorrhagia (in combination with ribavirin and peginterferon alfa), pallor (in combination with ribavirin and peginterferon alfa), pancreatitis (in combination with ribavirin and peginterferon alfa), photophobia (in combination with ribavirin and peginterferon alfa), photosensitivity (in combination with ribavirin and peginterferon alfa), retinal ischaemia (in combination with ribavirin and peginterferon alfa), retinopathy (in combination with ribavirin and peginterferon alfa), skin ulceration (in combination with ribavirin and peginterferon alfa), suicidal ideation (in combination with ribavirin and peginterferon alfa), tongue discoloration (in combination with ribavirin and peginterferon alfa), venous thromboembolism (in combination with ribavirin and peginterferon alfa),
              </p>
              <p>
                <strong>rare:</strong> Acute myocardial infarction (in combination with ribavirin and peginterferon alfa), aspermia (in combination with ribavirin and peginterferon alfa), bipolar disorder (in combination with ribavirin and peginterferon alfa), cholecystitis (in combination with ribavirin and peginterferon alfa), coronary artery disease (in combination with ribavirin and peginterferon alfa), encephalopathy (in combination with ribavirin and peginterferon alfa), hallucinations (in combination with ribavirin and peginterferon alfa), pericarditis (in combination with ribavirin and peginterferon alfa), pleural fibrosis (in combination with ribavirin and peginterferon alfa), respiratory failure (in combination with ribavirin and peginterferon alfa), sarcoidosis (in combination with ribavirin and peginterferon alfa), thyroid neoplasms (in combination with ribavirin and peginterferon alfa),
              </p>
              <p>
                <strong>notKnown:</strong> Rash with eosinophilia and systemic symptoms (in combination with ribavirin and peginterferon alfa), Stevens-Johnson syndrome (in combination with ribavirin and peginterferon alfa),
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA253</h3>
              <p outputclass="title">Boceprevir for chronic hepatitis C infection of genotype 1 (April 2012)</p> <p>Boceprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease:</p> <ul> <li>who have not been treated previously;</li> <li> in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA253">www.nice.org.uk/TA253</xref>
                <a href="http://www.nice.org.uk/TA253" target="_blank">www.nice.org.uk/TA253</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Coagulopathy
          </li>
          <li>
            hypoalbuminaemia
          </li>
          <li>
            low platelets
          </li>
          <li>
            predisposition to QT interval prolongation
          </li>
        </ul>
        <ul>
          <li>
            <p>Not recommended in patients with low platelets, hypoalbuminaemia, or coagulopathy&#8212;if initiated in these patients monitor closely for signs of infection, worsening liver impairment and anaemia (increased risk of severe morbidity and mortality).</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor full blood count before starting treatment and then on weeks 2, 4, 8, and 12 of treatment, then as indicated clinically.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of BOCEPREVIR</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76651"><a href="../medicinalForm/PHP76651.html" data-target="#PHP76651" data-action="load">Capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
